Athira’s experimental drug fosgonimeton failed to slow cognitive decline. The biotech firm says it’s not giving up.

Athira Pharma’s tumultuous journey to phase 2/3 Alzheimer’s disease data has ended in failure. | Athira Pharma’s tumultuous ...

Athira Pharma (NASDAQ:ATHA) shares fell over 75% after the company said fosgonimeton, its experimental therapy for ...

Athira Pharma said on Tuesday its investigative drug failed to meet the main goal in a mid-to-late stage trial in patients ...

Fosgonimeton, aimed at protecting neurons, failed to do better than placebo at slowing cognitive decline in patients with ...

The investigational injection fosgonimeton appeared to have better efficacy in patients with more severe disease, according ...

Athira Pharma, Inc. (NASDAQ:ATHA) stock is trading lower after the company released topline results from its Phase 2/3 ...

Athira Pharma (ATHA) saw its shares tailspin 81% after its lead candidate fosgonimeton failed the Phase II/III LIFT-AD ...

Athira Pharma Inc (ATHA) stock saw a decline, ending the day at $0.56 which represents a decrease of $-0.05 or -8.20% from the prior close of $0.61. The stock opened at $0.6 and touched a low of $0.54 ...

LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In ...

On Monday, Athira Pharma Inc (ATHA) stock saw a decline, ending the day at $0.49 which represents a decrease of $-0.05 or -9.26% from the prior close of $0.54. The stock opened at $0.53 and touched a ...

Athira Pharma saw its share crash 78.4% to $0.61 yesterday, after it announced another disappoint with its Alzheimer’s ...